^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MT-201

    i
    Other names: MT-201, MT-201-GBM monocyte vaccine, MT-201-GBM
    Associations

    News

    Trials
    Company:
    Duke University, Myeloid Therap
    Drug class:
    Immunostimulant, Cytotoxic T lymphocyte stimulant
    Related drugs:
    Associations

    News

    Trials
    over1year
    DEMAND: Monocyte Antigen Carrier Cells for Newly Diagnosed GBM (clinicaltrials.gov)
    P1, N=0, Withdrawn, Michael Gunn | N=27 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    MGMT (6-O-methylguanine-DNA methyltransferase) • IFNG (Interferon, gamma) • GZMB (Granzyme B)
    |
    temozolomide • MT-201
    almost2years
    DEMAND: Monocyte Antigen Carrier Cells for Newly Diagnosed GBM (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Michael Gunn | Trial completion date: Aug 2025 --> Nov 2025
    Trial completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase) • IFNG (Interferon, gamma) • GZMB (Granzyme B)
    |
    temozolomide • MT-201
    over2years
    DEMAND: Monocyte Antigen Carrier Cells for Newly Diagnosed GBM (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Michael Gunn | Trial completion date: Mar 2024 --> Aug 2025 | Trial primary completion date: Dec 2022 --> Feb 2025
    Trial completion date • Trial primary completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase) • IFNG (Interferon, gamma) • GZMB (Granzyme B)
    |
    temozolomide • MT-201
    3years
    DEMAND: Monocyte Antigen Carrier Cells for Newly Diagnosed GBM (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Michael Gunn | Trial completion date: Dec 2022 --> Mar 2024 | Initiation date: Dec 2021 --> Mar 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase) • IFNG (Interferon, gamma) • GZMB (Granzyme B)
    |
    temozolomide • MT-201 • adecatumumab (MT201)
    3years
    DEMAND: Monocyte Antigen Carrier Cells for Newly Diagnosed GBM (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Michael Gunn | Initiation date: Sep 2021 --> Dec 2021
    Trial initiation date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase) • IFNG (Interferon, gamma) • GZMB (Granzyme B)
    |
    temozolomide • MT-201 • adecatumumab (MT201)